Are DNA repair factors promising biomarkers for personalized therapy in gastric cancer? by Abdel-Fatah, Tarek et al.
FORUM NEWS & VIEWS
Are DNA Repair Factors Promising Biomarkers
for Personalized Therapy in Gastric Cancer?
Tarek Abdel-Fatah,1,* Arvind Arora,2,* Ipek Gorguc,2 Rachel Abbotts,2 Sarah Beebeejaun,3
Sarah Storr,2 Vivek Mohan,2 Claire Hawkes,3 Irshad Soomro,3 Dileep N. Lobo,4
Simon L. Parsons,5 and Srinivasan Madhusudan2
Abstract
Chronic inflammation is a driving force for gastric carcinogenesis. Reactive oxygen species (ROS) generated
during the inflammatory process generates DNA damage that is processed through the DNA repair pathways.
In this study, we profiled key DNA repair proteins (single-strand-selective monofunctional uracil-DNA glyco-
sylase 1 [SMUG1], Flap endonuclease 1 [FEN1], X-ray repair cross-complementing gene 1 [XRCC1], and Ataxia
telangiectasia mutated [ATM]) involved in ROS-induced oxidative DNA damage repair in gastric cancer and
correlated to clinicopathological outcomes. High expression of SMUG1, FEN1, and XRCC1 correlated to high
T-stage (T3/T4) ( p-values: 0.001, 0.005, and 0.02, respectively). High expression of XRCC1 and FEN1 also
correlated to lymph node-positive disease ( p-values: 0.009 and 0.02, respectively). High expression of XRCC1,
FEN1, and SMUG1 correlated with poor disease-specific survival (DSS) ( p-values: 0.001, 0.006, and 0.05, re-
spectively) and poor disease-free survival (DFS) ( p-values: 0.001, 0.001, and 0.02, respectively). Low expression
of ATM correlated to lymph node positivity ( p = 0.03), vascular invasion ( p = 0.05), and perineural invasion
( p = 0.005) and poor DFS ( p = 0.001) and poor DSS ( p = 0.003). In the multivariate Cox model, high XRCC1 and
low ATM were independently associated with poor survival ( p = 0.008 and 0.011, respectively). Our observation
supports the hypothesis that DNA repair factors are promising biomarkers for personalized therapy in gastric
cancer. Antioxid. Redox Signal. 18, 2392–2398.
Introduction
Chronic inflammation is a driving force for gastriccarcinogenesis (2). Reactive oxygen species (ROS) gen-
erated during the inflammatory process generate DNA
damaging lesions such as apurinic/apyrimidinic (AP) sites,
oxidized purines, and pyrimidines (such as 8-oxo-dG), DNA
single strand breaks (SSBs), oxidative-clustered DNA lesions,
and DNA double-strand breaks (DSBs) in cells. If unrepaired,
such DNA damaging lesions lead to accumulation of muta-
tions and eventually cancer (6). Interestingly, in cancer cells,
oncogenic transformation, enhanced metabolic activity, and
increased generation of ROS also result in substantial oxida-
tive stress compared to normal cells. Moreover tumor hypoxia
and an acidic tumor microenvironment may also promote
oxidative stress in cancer cells (7). Given the prevalence of
ROS in the tumor microenvironment, it is perhaps not sur-
prising that cancer cells, similar to normal cells, utilize
adaptive mechanisms to maintain cellular survival. Besides
the glutathione and thioredoxin systems, cells also up-
regulate antioxidant enzymes such as superoxide dismutases,
catalases, and peroxidases to process ROS (6). However,
cancer cells have a limited ROS buffering capacity, and ROS
accumulation eventually leads to cellular injury and accu-
mulation of DNA damage. Similar to normal cells, cancer
cells utilize the DNA repair machinery, although less effi-
ciently, to process damaging DNA lesions tomaintain cellular
survival (6).
Base excision repair (BER) is required for the accurate
removal of bases that have been damage by alkylation or
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oxidation (5). BER is performed by two major subpathways:
the short-patch pathway (SP-BER) and long-patch pathway
(LP-BER). The subpathways differ from each other in the
length of the repair patch and in the subsets of enzymes
involved. However, both pathways are initiated by a dam-
age-specific DNA glycosylase, which removes the damaged
base creating an abasic site (apurinic/apyrimidinic, AP site).
An AP endonuclease then cleaves the phosphodiester bond
5¢ to the AP site, thereby generating a nick with 5¢-sugar
phosphate (dRP) and 3¢-hydroxyl group. DNA polymerase
b adds the first nucleotide to the 3¢-end of the incised AP site.
Normally, the reaction continues through the short-patch
repair pathway where Pol b removes the 5¢-sugar phosphate
residue (by the process of b-elimination) and DNA ligase
III-X-ray repair cross-complementing gene 1 (XRCC1) het-
erodimer (or DNA ligase I) then completes the repair.
However, if the 5¢-sugar phosphate is resistant to b-elimi-
nation (such as due to oxidation), additional DNA synthesis
is then required and the repair process proceeds through the
LP-BER. In this pathway, replication factor C loads prolif-
erating cell nuclear antigen (PCNA) onto the DNA. PCNA
functions as a DNA sliding clamp for Pol d/e, which per-
forms DNA synthesis to displace the 5¢-sugar phosphate as
part of a flap. The flap is then removed by flap endonuclease
1 (FEN1), and DNA ligase I completes long-patch repair by
ligating the DNA ends (5).
ROS can also generate DNADSBs either directly or when a
replication fork encounters a SSB generated during oxidative
base damage repair. Ataxia telangiectasia mutated (ATM)
is critical for DNA DSB sensing and signal transduction.
Evolving evidence also suggests that ATM is also a sensor of
oxidative stress in cells. Moreover, ROS-induced ATM acti-
vation may also be independent of DSBs. ATM signaling
under oxidative stress may alter cellular metabolism, promote
cell survival, and induce expression of antioxidant enzymes to
maintain redox homeostasis (3).
Given the essential role of DNA repair in oxidative stress
and ROS-induced DNA damage, we hypothesized that
DNA repair may be dysregulated in human gastric adeno-
carcinomas. Here, we have investigated the expression of
single-strand-selective monofunctional uracil-DNA glycosy-
lase 1 (SMUG1), XRCC1, FEN1, and ATM in gastric cancer
patients.
Patient demographics are summarized in Table 1. A total of
142 patients underwent primary surgery for gastric adeno-
carcinoma. Median age was 74 years and 74% were male.
Majority of tumors were T3 (53%); 77% of tumors were N1 or
greater disease; 49% of patients underwent total gastrectomy;
62% patients were dead and 38% cases were alive at the time
of analysis.
Single-Strand-Selective Monofunctional Uracil-DNA
Glycosylase 1
SMUG1 glycosylase is a key enzyme for repairing
5-hydroxymethyluracil, 5 formyluracil, 5,6-dihydrouracil,
alloxan, and other lesions generated during oxidative base
damage (1). We investigated SMUG1 expression in gastric
cancers. A total of 112 cores were suitable for analyses. About
38/112 (34%) showed negative SMUG1 expression and
74/112 (66%) showed positive SMUG1 expression (Fig. 1)
(Table 2). SMUG1-positive tumors weremore likely to be high
T stage (T3 or T4) ( p = 0.02). Patients whose tumors were
SMUG1-positive had poor adverse clinical outcome. The
mean disease-specific survival (DSS) in SMUG1-positive
patients was 49.1 months (95% confidence interval [CI]
38.6–59.6) compared to 60.09 months (95% CI 47.6–72.5) in
SMUG1-negative patients ( p= 0.05) (Fig. 2A). The mean dis-
ease free survival (DFS) in SMUG1-positive patients was 47.3
months (95% CI 36.24–59.4) compared to 62.2 months (95%
CI 50.0–74.4) in SMUG-1-negative patients ( p= 0.02) (Fig. 2B).
Innovation
Reactive oxygen species (ROS) generated during in-
flammation induces DNA damage that is processed
through DNA repair in cells. Whereas suboptimal DNA
repair may predispose to cancer, evolving data also sug-
gest that established tumors are under enormous oxidative
stress, and dysregulation of ROS-induced DNA damage
repair may in fact be essential for cancer cell survival. To
test this hypothesis, the authors profiled DNA repair
proteins and demonstrated that overexpression of single-
strand-selective monofunctional uracil-DNA glycosylase 1
(SMUG1), Flap endonuclease 1 (FEN1), and X-ray
repair cross-complementing gene 1 (XRCC1) and down-
regulation of Ataxia telangiectasia mutated (ATM) corre-
late to adverse clinicopathological features in patients. The
data suggest that ROS-induced DNA repair factors are
promising biomarkers for personalized therapy in gastric
cancer.
Table 1. Patients’ Demographics
Number (%)
Total number of patient 142
Median age 74 years
Sex
Male 105 (73.9%)
Female 37 (26%)
T stage
T1 14 (9.8%)
T2 48 (33.8%)
T3 75 (52.8%)
T4 5 (3.5%)
N stage
N0 33 (23.2%)
‡N1 109 (76.8%)
M stage
M0 140 (98.5%)
M1 2 (1.4%)
Tumor type
Adenocarcinoma 142 (100%)
Site of tumor
Gastric 142 (100%)
Surgery
Total gastrectomy 70 (49%)
Partial gastrectomy 52 (37%)
Oesophago-gastrectomy 20 (14%)
Survival status
Alive 54 (38%)
Dead 87 (62%)
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Flap Endonuclease 1
FEN1 structure-specific endonuclease is essential for long-
patch BER involved in processing oxidative base damage in
cells (9). A total of 127 cores were suitable for FEN1 analyses.
About 53/127 (42%) showed negative FEN1 expression and
74/127 (58%) showed positive FEN1 expression (Fig. 1) (Table
2). FEN1-positive tumors were more likely to be high T stage
(T3 or T4) ( p= 0.005) with lymph node positivity ( p= 0.02).
The mean DSS in FEN1-positive patients was 42.6 months
(95% CI 33.3–52.0) compared to 62.9 months (95% CI 52.7–
73.1) in FEN1-negative patients ( p = 0.006) (Fig. 2D). The
mean DFS in FEN1-positive patients was 39.8 months (95%CI
29.6–49.9) compared to 71.4 months (95% CI 60.0–82.8) in
FEN1-negative patients ( p = 0.001) (Fig. 2C).
X-Ray Repair Cross-Complementing Gene 1
XRCC1 plays a critical role in BER (5). XRCC1, a 70-kDa
protein, has three functional domains: an N-terminal DNA
binding domain, a centrally located BRCT I domain, and
a C-terminal BRCT II domain. Although XRCC1 has no
known enzymatic activity, it functions as a molecular scaf-
fold protein and is intimately involved in the coordination of
DNA repair by interacting with several components of the
BER/SSBR pathway such as DNA glycosylases, apurinic/
apyrimidinic endonulcease (APE1), PARP-1, polynulceotide
kinase, and ligase III involved in the repair of oxidative base
damage (5). A total of 106 cores were suitable for XRCC1
analyses. About 66/106 (62%) showed negative XRCC1
expression and 40/106 (38%) showed positive XRCC1 ex-
pression (Fig. 1) (Table 2). XRCC1-positive tumors were
more likely to be high T stage (T3 or T4) ( p= 0.009) and were
lymph node-positive ( p = 0.001). The mean DSS in XRCC1-
positive patients was 30.3 months (95% CI 21.3–39.4) com-
pared to 63.5 months (95% CI 52.9–74.2) in XRCC1-negative
patients ( p = 0.001) (Fig. 3A).The mean DFS in XRCC1-
positive patients was 29.7 months (95% CI 20.5–38.9)
compared to 64.02 months (95% CI 52.85–75.2) in XRCC1-
negative patients ( p= 0.001) (Fig. 3B).
FIG. 1. Microphotographs of tumors expressing high
levels of (A) SMUG1, (B) FEN1, (C) XRCC1, and (D) ATM
(magnification · 100). See methods for details. SMUG1,
single-strand-selective monofunctional uracil-DNA glycosylase
1; FEN1, Flap endonuclease 1; XRCC1, X-ray repair cross-
complementing gene 1; ATM, Ataxia telangiectasia mutated.
To see this illustration in color, the reader is referred to the web
version of this article at www.liebertpub.com/ars
Table 2. Clinicopathological Correlations
SMUG 1 FEN1 XRCC1 ATM
Variable Low High
p-
Value Low High
p-
Value Low High
p-
Value Low High
p-
Value
T stage
T1and T2 (n = 61) 21 (55.3) 25 (33.8) 0.02 32 (60.4) 26 (35.1) 0.005 35 (53) 8 (20) 0.001 23 (39.7) 20 (57.1) 0.1
T3 and T4 (n= 79) 17 (44.7) 49 (66.2) 21 (39.6) 48 ( 64.9) 31 (47) 32 (80) 35 (60.3) 15 (42.9)
N stage
N0 (n = 33) 11 (28.9) 13 (17.6) 0.16 18 (34) 12 (16.2) 0.02 19 (28.8) 3 (7.5) 0.009 10 (17.2) 13 (37.1) 0.03
N1–3 (n = 107) 27 (71.1) 61 (82.4) 35 (66) 62 (83.8) 47 (71.2) 7 (92.5) 48 (82.8) 22 (62.9)
Vascular invasion
Absent (n= 44) 12 (31.6) 20 ( 27) 0.614 18 (34) 21 (28.4) 0.5 21 (31.8) 9 ( 22.5) 0.302 14 (24.1) 15 (42.9) 0.05
Present (n = 96) 26 (68.4) 54 (73) 35 (66) 53 (71.6) 45 (68.2) 31 (77.5) 44 (75.9) 20 (57.1)
Perineural invasion
Absent (n= 75) 21 (55.3) 36 (48.6) 0.5 30 (56.6) 37 (50) 0.46 37 (56.1) 16 (40) 0.109 19 (32.8) 22 (62.9) 0.005
Present (n = 65) 17 (44.7) 38 (51.4) 23 (43.4) 37 (50) 29 (43.9) 24 (60) 39 (67.2) 13 (37.1)
SMUG1, single-strand-selective monofunctional uracil-DNA glycosylase 1; FEN1, Flap endonuclease 1; XRCC1, X-ray repair cross-
complementing gene 1; ATM, Ataxia telangiectasia mutated.
Bold numbers indicate significant p-values.
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ATM Kinase
ATM is critical for DNA DSB sensing and signal trans-
duction (3). As ROS-induced DNA damage can generate
DSBs, we investigated ATM expression. A total of 96 cores
were suitable for ATM analyses. About 58/96 (60.5%) showed
negative ATM expression and 38/96 (39.5%) showed positive
ATM expression (Fig. 1) (Table 2). ATM-negative tumorswere
more likely to be lymph node-positive ( p= 0.03) and associ-
ated with vascular invasion ( p = 0.05) and peri-neural inva-
sion ( p= 0.005). The mean DSS in ATM-negative patients was
47.6 months (95% CI 36.1–59.1) compared to 72.1 months
(95% CI 62.3–81.8) in ATM-positive patients ( p = 0.003) (Fig.
3C). The mean DFS in ATM-negative patients was 44.7
months (95% CI 32.8–56.6) compared to 73.2 months (95% CI
63.3–83.1) in ATM-positive patients ( p= 0.001) (Fig. 3D).
Multivariate Cox Regression Analysis
Univariate analyses conducted above provide evidence
that DNA repair is frequently altered in gastric cancer. To
investigate whether DNA repair factors are independent
biomarkers, a multivariate Cox regression analysis including
other validated prognostic factors, such as T-stage, lymph
node stage, and histological grade, was conducted. High
XRCC1 and low ATMwere powerful independent predictors
for DSS ( p = 0.008 and 0.011, respectively) and DFS ( p = 0.032
and 0.009, respectively) (Table 3).
Concluding Remarks and Future Directions
Altered DNA repair may impact upon repair of DNA
damage induced by ROS generated during inflammation in
cells. Evolving evidence also suggests that dysregulated DNA
repair in tumors may also affect cancer biology and select for
aggressive clones with enhanced survival potential. Our data
support the hypothesis that cancer cells are under consider-
able oxidative stress compared to normal cells and that up-
regulation of BER (SMUG1, FEN1, and XRCC1) is essential for
the repair of oxidative base damage and survival in cancer
cells. Interestingly, ATM is frequently downregulated in
FIG. 2. Kaplan Meier curves for SMUG1 (A, DSS; B, DFS) and FEN1 (C, DSS; D, DFS). DSS, disease-specific survival
(months); DFS, disease free survival (months).
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gastric cancer and correlates with adverse features. Our data
are also consistent with a recent study by Kang et al., who
investigated ATM in 70 gastric cancers and demonstrated that
low levels of ATM correlated to poor differentiation, lymph
node metastasis, and poor 5-year survival (4). Taken together,
the data, including ours, suggest that loss of ATM expression
may be an important prognostic marker in gastric cancer. In
multivariate analyses, overexpression of XRCC1 and down-
regulation of ATM were independently associated with poor
survival. Our result is consistent with recent preclinical ob-
servations that BER and DSB repair may be differentially ex-
pressed in the tumor microenvironment. Hypoxia and acidic
tumor microenvironment, besides increasing oxidative stress
and inducing BER upregulation, have also been shown to
suppress DSB repair, including homologous recombination
(HR) (7). Our study suggests that this phenomenon may be
operating gastric cancers. The ability of PARP inhibitors (that
block BER and SSBR) to induce synthetic lethality in BRCA-
deficient breast and ovarian cancer suggests that this
approach may be feasible in other HR-deficient systems such
as tumors deficient in ATM. AsATM is a key player in HR,we
speculate that ATM-deficient tumors could be targeted by
FIG. 3. Kaplan Meier curves for XRCC1 (A, DSS; B, DFS) and ATM (C, DSS; D, DFS).
Table 3. Multivariate Analysis
95% CI for Exp(B)
p-Value Exp(B) Lower Upper
Disease-specific survival
ATM 0.011 0.227 0.072 0.711
XRCC1 0.008 3.429 1.378 8.532
SMUG1 0.538 1.410 0.473 4.208
FEN1 0.274 0.535 0.175 1.639
T stage 0.100 2.082 0.870 4.982
N stage 0.005 2.420 1.312 4.463
Grade 0.739 1.107 0.609 2.011
Disease free survival
ATM 0.009 0.240 0.082 0.701
XRCC1 0.032 2.599 1.088 6.211
SMUG1 0.391 1.594 0.550 4.626
FEN1 0.638 0.773 0.265 2.258
T stage 0.147 1.809 0.811 4.035
N stage 0.014 2.049 1.159 3.623
Grade 0.996 1.001 0.551 1.819
CI, confidence interval.
Bold numbers indicate significant p-values.
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BER inhibitors. We have recently demonstrated that this ap-
proach is feasible using human APE1 inhibitors that block
BER in cells (8). APE1 inhibitors were synthetically lethal in
ATM-deficient cells in that study (8). The data also imply that
BER inhibition such as by targeting other factors such as
FEN1, SMUG1, or XRCC1 may also be an interesting future
approach for personalized therapy in gastric cancer.
Notes
Patients
Investigation of the expression of SMUG1, XRCC1, FEN1,
and ATM in gastro-oesophageal cancers was carried out in 142
gastric adenocarcinoma cases treated at Nottingham Uni-
versity Hospitals (NUH) between 2001 and 2006. Patient de-
mographics is summarized in Table 1. Median age was 74
years; 74% were male; 53% had T3 tumors. Patients in this
cohort received primary surgery only and did not receive any
adjuvant chemotherapy. Survival was calculated from the date
of diagnosis until January 13, 2009, when any remaining sur-
vivors were censored. The conduct of this study was approved
by the Ethics Committee of Nottingham University Hospitals.
Construction of tissue microarray
Tissuemicroarrays (TMAs) were constructed. In short, area-
specialized histopathologists identified and marked formalin-
fixed paraffin-embedded tissue blocks containing tumor tissue
on hematoxylin and eosin-stained slides. The marked areas in
these donor paraffin blocks were used to construct the TMA.
Triplicate tissue cores with a diameter of 0.6mm were taken
from the marked areas and arrayed into a recipient paraffin
block using a tissue puncher/arrayer (Beecher Instruments).
Five-micron sections of the tissue array block were cut and
placed on Fisherbrand Colorfrost/Plus microscope slides
(Fisher Scientific) for immunohistochemical staining.
Immunohistochemistry
A standard streptavidin-biotin-peroxidase complex meth-
odwas used. Negative controls were obtained by omitting the
primary antibody in each case. The tissue slides were depar-
affinized with xylene and then rehydrated through five
decreasing concentrations of alcohol (100%, 90%, 70%, 50%,
and 30%) for 2min each. Endogenous peroxidise activity was
blocked by incubation in a 1% hydrogen peroxide/methanol
buffer. Antigen retrieval was carried out by microwave
treatment of the slides in sodium citrate buffer (pH 6.0) for
10min. The slides were rinsed in phosphate buffer solution
(PBS) and incubated with blocking serum diluted in PBS to
block nonspecific staining. The following primary antibodies
were used in the current study: 1/200 dilution of Goat anti-
SMUG1monoclonal antibody (Acris AntibodyGmbH), 1/200
dilution of anti-FEN1 rabbit polyclonal antibody (NBP1-
67924; Novus Biologicals), 1:200 dilution of anti-XRCC1mouse
monoclonal antibody (Ab-1, clone 33-2-5; Thermoscientific),
and 1/100 anti-ATMRabbitmonoclonal antibody (Clone Y170;
Abcam). All primary antibody dilutions were made in PBS.
After washing with PBS, sections were incubated with the
secondary antibody (Vector Labs) for 30min followed by the
avidin-biotin complex for a further 30min. 3-3¢ Diamino-
benzidine tetrahydochloride was used as a chromogen. All
sections were counterstained with Gill’s hematoxylin.
Evaluation of immune staining
The tumorcoreswereevaluatedby twospecialistpathologists
blinded to the clinicopathological characteristics of patients, in
two different settings. There was excellent intra- and inter-
observer agreements (k>0.8; Cohen’s k and multi-rater k tests,
respectively. Whole field inspection of the core was scored and
intensities of nuclear or cytoplasmic staining were grouped as
follows: 0=no staining, 1=weak staining, 2=moderate staining,
3= strong staining. The percentage of each category was esti-
mated (0%–100%). H-score (range 0–300) was calculated by
multiplying intensity of staining and percentage staining. Low/
negative XRCC1 expression was defined by mean of H-score
of £100. Low/negative FEN1 expression was defined by mean
of H-score of £100. Low/negative SMUG1 expression was de-
fined by mean of H-score of £100. H-score of > 100 was con-
sidered positive marker expression. Low/negative ATM
expression was defined as % staining of £25% in tumor cores.
Not all cores within the TMA were suitable for immunohisto-
chemistryanalysisduetomissingcoresorabsenceof tumorcells.
Statistical analysis
Statistical analysis of data was performed using SPSS ver-
sion 20.0 for Windows (SPSS, Inc.). Univariate analysis of
associations was determined using the Pearson Chi-squared
(v2) test. Survival rates were calculated from the time of
diagnosis until the end of the follow up period and Kaplan
Meier curves were plotted. The statistical significance of
differences between survival rates was determined using the
log-rank test. Survival was censored if the patient was still
alive. p-values< 0.05 were identified as statistically signifi-
cant. Multivariate analysis was performed by Cox Propor-
tional Hazards regression model.
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Abbreviations Used
ATM¼Ataxia telangiectasia mutated
BER¼ base excision repair
DFS¼disease free survival
DNA¼deoxyribonucleic acid
DSBs¼double strand breaks
DSS¼disease-specific survival
FEN1¼ Flap endonuclease 1
LP-BER¼ long patch base excision repair
PBS¼phosphate buffer solution
PCNA¼proliferating cell nuclear antigen
ROS¼ reactive oxygen species
SMUG1¼ single-strand-selective monofunctional
uracil-DNA glycosylase 1
SP-BER¼ short patch base excision repair
TMAs¼ tissue microarrays
XRCC1¼X-ray repair cross-complementing gene 1
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